UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

NOTICE OF EFFECTIVENESS

Effective Date:November 29,
ABVC BioPharma (NASDAQ:ABVC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more ABVC BioPharma Charts.
ABVC BioPharma (NASDAQ:ABVC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more ABVC BioPharma Charts.

Abvc Biopharma, Inc. News

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
Thursday 18 April 2024 (1 week ago) • GlobeNewswire Inc.
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Wednesday 17 April 2024 (1 week ago) • GlobeNewswire Inc.
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
Wednesday 10 April 2024 (2 weeks ago) • GlobeNewswire Inc.
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
Tuesday 26 March 2024 (1 month ago) • GlobeNewswire Inc.
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
Thursday 21 March 2024 (1 month ago) • GlobeNewswire Inc.
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
Tuesday 19 March 2024 (1 month ago) • GlobeNewswire Inc.
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
Friday 15 March 2024 (1 month ago) • GlobeNewswire Inc.
Form 8-K/A - Current report: [Amend]
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K/A - Current report: [Amend]
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)
ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
Wednesday 28 February 2024 (2 months ago) • GlobeNewswire Inc.
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Saturday 17 February 2024 (2 months ago) • Edgar (US Regulatory)
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
Friday 16 February 2024 (2 months ago) • GlobeNewswire Inc.

More Abvc Biopharma, Inc. News Articles